Clinical Study

Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China

Table 4

Adverse events frequency and severity.

SOF+DCV 
N=96
SOF+LDV 
N=99
SOF+VEL 
N=31
Total 
N=226

Fatigue18(19%)34(34%)6(19%)58(26%)
Diarrhea8(8%)13(13%)2(6%)23(10%)
Headache16(17%)14(14%)2(6%)33(15%)
Nausea10(10%)6(7%)3(10%)19(8%)
Vomiting4(4%)7(7%)2(6%)13 (6%)
Insomnia7(7%)14(14%)4(13%)25(11%)
Dizziness6(6%)21(21%)3(10%)30(13%)
Cough6(6%)12(12%)5(16%)23(10%)
Adverse event leading to discontinuation0000
HCC occurrence during therapy0000
HCC occurrence during 12 weeks of follow-up period0000